Rogério Vivaldi Coelho
Chief Executive Officer presso SIGILON THERAPEUTICS, INC.
Patrimonio netto: 514 910 $ in data 31/07/2023
Profilo
Rogério Vivaldi Coelho was the founder of Minerva Neurosciences, Inc. (founded in 2007) where he held the title of President, Chief Executive Officer & Director in 2014.
He is currently the Chief Executive Officer at Sigilon Therapeutics, Inc. (since 2018) and an Independent Director at Crinetics Pharmaceuticals, Inc. (since 2022).
In his former positions, he served as a Director at Mind-NRG SARL in 2014, President-Rare Disease, Renal & Endocrine, SVP at Genzyme Corp.
from 1997 to 2014, Chief Commercial Officer at Spark Therapeutics, Inc. from 2015 to 2016, and Chief Global Therapeutics Officer & Executive VP at Bioverativ, Inc. from 2016 to 2018.
Dr. Vivaldi Coelho holds a doctorate degree from the Federal University of Rio de Janeiro and an MBA from COPPEAD Graduate School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 16/06/2023 | 11 000 ( 0.01% ) | 514 910 $ | 31/03/2024 | |
| 11/08/2023 | 0 ( -.--% ) | - $ | 31/07/2023 |
Posizioni attive di Rogério Vivaldi Coelho
| Società | Posizione | Inizio |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Chief Executive Officer | 14/08/2018 |
| CRINETICS PHARMACEUTICALS, INC. | Director/Board Member | 03/01/2022 |
Precedenti posizioni note di Rogério Vivaldi Coelho
| Società | Posizione | Fine |
|---|---|---|
| BIOVERATIV INC | Corporate Officer/Principal | 01/01/2018 |
| SPARK THERAPEUTICS, INC. | Director/Board Member | 05/01/2015 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| MINERVA NEUROSCIENCES, INC. | Founder | 20/11/2014 |
Mind-NRG SARL
 Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Director/Board Member | 20/11/2014 |
Formazione di Rogério Vivaldi Coelho
| Federal University of Rio de Janeiro | Doctorate Degree |
| COPPEAD Graduate School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MINERVA NEUROSCIENCES, INC. | Health Technology |
| CRINETICS PHARMACEUTICALS, INC. | Health Technology |
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Mind-NRG SARL
Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Health Services |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Rogério Vivaldi Coelho
